Clinical Trial Update: Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients. [Phase 2]

View source ↗

Summary

Open-label Phase II trial evaluating escalating doses of bicalutamide for biochemical failure in prostate cancer patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• bicalutamide (bicalutamide)

Snippet

Sponsor: Canadian Urology Research Consortium | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED